Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An update on current management of advanced renal cell cancer, biomarkers, and future directions.

Literature DB >> 25722991

An update on current management of advanced renal cell cancer, biomarkers, and future directions.

Abstract

In the past decade, metastatic renal cell carcinoma (mRCC) treatment underwent significant advancement that resulted in an unprecedented improvement in the prognosis of this disease. This review will provide an updated review of currently approved treatment options, namely antiangiogenic and immunotherapy, as well as treatment guideline recommended by the National Comprehensive Cancer Network (NCCN). We will summarize studies ongoing in determining prognostic and predictive biomarkers in maximizing therapeutic benefit in the treatment of this disease. Lastly, we will discuss promising agents in clinical testing.

Entities: CellLine Chemical Disease Gene Species

Keywords: IL-2; Renal cell carcinoma; VEGF pathway; anti-CTLA-4 antibody; anti-PD-1 antibody; immunotherapy; mTOR pathway; monoclonal antibody; target therapy; tyrosine kinase inhibitor

Year: 2014 PMID： 25722991 PMCID： PMC4339053

Source DB: PubMed Journal: Ann Cancer Res

82 in total

1. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors: R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245

2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245

3. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Authors: Toni K Choueiri; André P Fay; Robert Gagnon; Ying Lin; Brittany Bahamon; Victoria Brown; Jonathan E Rosenberg; Thomas E Hutson; Katherine L Baker-Neblett; Christopher Carpenter; Yuan Liu; Lini Pandite; Sabina Signoretti
Journal: Clin Cancer Res Date: 2013-07-23 Impact factor: 12.531

4. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.

Authors: Ana M Molina; Darren R Feldman; Martin H Voss; Michelle S Ginsberg; Michael S Baum; Dion R Brocks; Patricia M Fischer; Michael J Trinos; Sujata Patil; Robert J Motzer
Journal: Cancer Date: 2011-09-06 Impact factor: 6.860

5. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors: Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal: Proc Natl Acad Sci U S A Date: 2010-02-16 Impact factor: 11.205

6. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.

Authors: Daniel Cho; Sabina Signoretti; Sandra Dabora; Meredith Regan; Apryle Seeley; Mauro Mariotti; Amanda Youmans; Adam Polivy; Lucy Mandato; David McDermott; Eric Stanbridge; Michael Atkins
Journal: Clin Genitourin Cancer Date: 2007-09 Impact factor: 2.872

7. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Authors: Thomas E Hutson; Bernard Escudier; Emilio Esteban; Georg A Bjarnason; Ho Yeong Lim; Kenneth B Pittman; Peggy Senico; Andreas Niethammer; Dongrui Ray Lu; Subramanian Hariharan; Robert J Motzer
Journal: J Clin Oncol Date: 2013-12-02 Impact factor: 44.544

8. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

Authors: Brian B Hasinoff; Xing Wu; John L Nitiss; Ragu Kanagasabai; Jack C Yalowich
Journal: Biochem Pharmacol Date: 2012-10-05 Impact factor: 5.858

9. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

Authors: Ana M Molina; Thomas E Hutson; James Larkin; Anne M Gold; Karen Wood; Dave Carter; Robert Motzer; M Dror Michaelson
Journal: Cancer Chemother Pharmacol Date: 2013-11-05 Impact factor: 3.333

10. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.

Authors: Brian I Rini; David I Quinn; Michael Baum; Laura S Wood; Jamal Tarazi; Brad Rosbrook; Lillian Shahied Arruda; Laura Cisar; W Gregory Roberts; Sinil Kim; Robert J Motzer
Journal: Target Oncol Date: 2014-03-05 Impact factor: 4.493

4 in total

4. Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma.

Authors: Sung Han Kim; Weon Seo Park; Sun Ho Kim; Ho Kyung Seo; Jae Young Joung; Kang Hyun Lee; Jinsoo Chung
Journal: PLoS One Date: 2017-05-31 Impact factor: 3.240